此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Effect of an Anti-inflammatory Diet in Patients With Rheumatoid Arthritis (DAIAR)

2022年4月19日 更新者:Universidade Nova de Lisboa

The Effect of an Anti-inflammatory Diet on Disease Activity and Quality of Life in Patients With Rheumatoid Arthritis - Parallel Controlled Randomized Clinical Trial

Rheumatoid arthritis (RA) is an autoimmune disease that affects 0.5-1% of the population and in which his remission is not always achieved, affecting physical and mental well-being and quality of life (QL). As a complement to pharmacotherapy, dietary intervention should be evaluated as a treatment option.

The main objective of this parallel controlled randomized clinical trial is to check the effect of an anti-inflammatory dietary intervention, compared to a diet based on the principles of the Mediterranean diet (control), on disease activity (AD) and improving QL.

Patients will be instructed to follow an anti-inflammatory diet (DAI) or a control diet (DC) for 6 months. The AD and QL will be evaluated at the end of the intervention.

As there are no dietary guidelines for RA, this study aims to provide scientific evidence about the impact of diet therapy on reducing AD and improving QL.

研究概览

详细说明

The main objective of this trial is to check the effect of an DAI, compared to a DC, on reducing AD and improving QL.

As secondary objectives, it is intended to investigate the relationship of DAI with inflammatory markers and with the modulation of the composition / diversity of the intestinal microbiota, in comparison with a DC.

This study combines all dietary components with an anti-inflammatory effect, thus allowing the possibility of evaluating the full potential of dietary treatment in the disease, including intestinal microbiota modulation.

These results are intended to further contribute to clinical decision making and better evidence-based treatment.

研究类型

介入性

注册 (实际的)

26

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Portimão、葡萄牙
        • Hospital Particular do Algarve - HPA Saúde

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age over 18 years;
  • Presence of active disease, (DAS28≥ 2.6), under adequate control and medication.
  • Able to sign informed consent

Exclusion Criteria:

  • Any type of psychological deficiency, dementia or eating disorder;
  • Presence of food allergies and / or intolerances;
  • Be vegetarian or use Phytotherapy or other supplements (namely, pre and probiotics);
  • Use of antibiotics im the last 6 months;
  • Have had previous nutritional monitoring or change in eating habits in the last 6 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
其他:Diet Control
Diet Control (DC): nutritional education and adherence monitoring. DC will be based on the Portuguese "Nova Roda dos Alimentos" following the principles of the Mediterranean diet.
Diet following mediterranean principles, for 15 weeks
实验性的:Diet Anti-inflammatory
Diet Anti-inflammatory (DAI): nutritional education and adherence monitoring. The DAI dietary intervention will be based on combining individual food items described as potential anti-inflammatory mitigators.
Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Changes in disease activity
大体时间:15 weeks
Difference between the intervention and control group in the changes in Disease Activity (using DAS28 score: greater than 2,6 implies active disease), from baseline to the end of follow-up
15 weeks
Changes in Quality of Life
大体时间:15 weeks
Difference between the intervention and control group in changes in Quality of Life (Health Assessment Questionnaire (HAQ): scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability), from baseline to the end of follow-up
15 weeks

次要结果测量

结果测量
措施说明
大体时间
Changes in C-Reactive Protein (CRP)
大体时间:15 weeks
Difference between the intervention and control group in changes in C-Reactive Protein (CRP) measured in mg/L, from baseline to the end of follow-up
15 weeks
Changes in Erythrocyte Sedimentation Rate (ESR)
大体时间:15 weeks
Difference between the intervention and control group in changes in Erythrocyte Sedimentation Rate (ESR) measured in mm/h, from baseline to the end of follow-up
15 weeks
Changes in Rheumatoid Factor (RF)
大体时间:15 weeks
Difference between the intervention and control group changes in Rheumatoid Factor (RF) measured in IU/mL, from baseline to the end of follow-up
15 weeks
Changes in Gut microbiota
大体时间:15 weeks

Difference between the intervention and control group in the change of gut microbiota from baseline to the end of follow-up.

Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.

15 weeks
Changes in weight
大体时间:15 weeks
Difference between the intervention and control group changes in weight, measured in Kg, from baseline to the end of follow-up
15 weeks
Changes in Body Mass Index (BMI)
大体时间:15 weeks
Difference between the intervention and control group changes in BMI, calculated using weight and height, presented in kg/m2: underweight < 18,5; normoweight 18,6-24,9; overweight 25-29,9; obese >30, from baseline to the end of follow-up
15 weeks
Changes in waist circumference perimeter
大体时间:15 weeks
Difference between the intervention and control group changes in waist circumference perimeter, measured in cm, from baseline to the end of follow-up
15 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年4月1日

初级完成 (实际的)

2021年12月20日

研究完成 (实际的)

2021年12月20日

研究注册日期

首次提交

2022年3月25日

首先提交符合 QC 标准的

2022年4月19日

首次发布 (实际的)

2022年4月20日

研究记录更新

最后更新发布 (实际的)

2022年4月20日

上次提交的符合 QC 标准的更新

2022年4月19日

最后验证

2022年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅